Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9% - Still a Buy?

Key Points

• Sana Biotechnology shares rose 8.9% to about $3.95, while trading volume was 81% below its average daily level. The company has a $1.20 billion market capitalization and remains unprofitable, with a negative P/E ratio.
• Analyst sentiment is broadly positive: seven analysts rate the stock a Buy, one rates it Hold and one rates it Sell, producing a “Moderate Buy” consensus and an average price target of $9.33. However, Bank of America recently cut its target to $6, while other firms have issued substantially different views.
• Sana reported a quarterly loss of $0.13 per share, beating estimates for a $0.15 loss; analysts expect a full-year loss of $0.61 per share. Institutional investors own 88.23% of the stock, and the company is developing engineered cell therapies for cancer, genetic disorders and other serious diseases.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report)'s stock price traded up 8.9% during trading on Wednesday . The company traded as high as $3.91 and last traded at $3.9540. 589,720 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 3,099,797 shares. The stock had previously closed at $3.63.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SANA. Bank of America reduced their price objective on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating for the company in a research note on Friday, August 14th. Wall Street Zen downgraded Sana Biotechnology from a "hold" rating to a "sell" rating in a report on Monday, July 20th. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research report on Monday, May 11th. They set a "buy" rating and a $16.00 price objective for the company. Finally, Weiss Ratings raised Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, July 23rd. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Sana Biotechnology presently has an average rating of "Moderate Buy" and a consensus price target of $9.33.

Sana Biotechnology Stock Up 10.1%

The firm has a market capitalization of $1.20 billion, a PE ratio of -5.26 and a beta of 2.16. The business has a 50-day moving average price of $3.40 and a 200-day moving average price of $3.43.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. On average, equities research analysts anticipate that Sana Biotechnology, Inc. will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds have recently modified their holdings of SANA. Walleye Capital LLC purchased a new stake in shares of Sana Biotechnology in the 2nd quarter valued at approximately $35,000. Royal Bank of Canada raised its position in shares of Sana Biotechnology by 76.8% during the 1st quarter. Royal Bank of Canada now owns 12,285 shares of the company's stock valued at $35,000 after buying an additional 5,338 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in Sana Biotechnology in the third quarter valued at approximately $36,000. Rockefeller Capital Management L.P. lifted its holdings in Sana Biotechnology by 74.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock valued at $39,000 after acquiring an additional 4,088 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Sana Biotechnology in the third quarter worth approximately $39,000. Hedge funds and other institutional investors own 88.23% of the company's stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source